Data on anti-SARS-CoV-2 monoclonal antibodies efficacy came from clinical studies that enrolled unvaccinated patients. The implementation of massive vaccination campaigns has now considerably reduced the health burden related to COVID-19 in Italy, and treatment options for early-stage disease, such as monoclonal antibodies or antivirals, are nowadays used to treat many vaccinated people with breakthrough COVID-19 infections. Few articles have reported the clinical efficacy of monoclonal antibodies in vaccinated individuals with breakthrough COVID-19. In our retrospective study, we examined patients vaccinated with Pfizer-BioNTech, Moderna, Astra-Zeneca and Janssen Johnson & Johnson vaccines and eligible for treatment with monoclonal antibodies, enrolled from 1st September 2021 to 15th January 2022. None of the patients who refused to get monoclonal antibody treatment died or were hospitalized for severe disease, suggesting that vaccinated patients do not need to be treated. This article is protected by copyright. All rights reserved.
Is monoclonal antibody administration necessary in all vaccinated patients with breakthrough COVID‐19 infections?